| # | Title | Authors | Keywords |
|---|---|---|---|
| P115 | Predictive and pharmacodynamic biomarkers associated with treatment with the oral selective AXL Inhibitor bemcentinib in combination with pembrolizumab in patients with advanced NSCLC and Melanoma | Robert Holt, PhD; David Micklem, PhD; Anthony Brown; Cornelia Schuster; Oddbjørn Straume; James Lorens, PhD | Biomarkers; Checkpoint blockade; Chemokine; Clinical study; Clinical trial; Coinhibition; Cytokine; Targeted therapy |
